Loading organizations...
dMed is a technology company.
dMed, operating as Caidya, is a global clinical research organization supporting pharmaceutical and medical device companies. It accelerates new therapy development through full-service capabilities, including regulatory strategy, clinical operations, biometrics, and quality management. Its approach emphasizes data-driven decision-making and operational expertise across therapeutic areas.
Founded in August 2016 by Dr. Lingshi Tan, an experienced biopharmaceutical leader, dMed addressed the need for a globally integrated, high-quality clinical trial service provider. Dr. Tan's insight aimed to navigate the complex drug development landscape by building a robust platform, specifically bridging Western and Asian markets for intricate research.
dMed serves biopharmaceutical and medical device innovators pursuing efficient clinical development. The company's vision, now under the Caidya brand, is to liberate clinical research and deliver life-changing therapies globally. This mission is achieved through continuous operational excellence and strategic expansion, ensuring broad access to diverse patient populations and therapeutic expertise.
dMed has raised $214.0M across 5 funding rounds.
dMed has raised $214.0M in total across 5 funding rounds.
dMed has raised $214.0M in total across 5 funding rounds.
dMed's investors include Springhill Fund, Fidelity Management & Research Company, Hongshan Capital Group (Sequoia Capital China), Kaiser Permanente, Rock Springs Capital, Superstring Capital, Qiming Venture Partners, Lilly Asia Ventures, Vivo Capital, Legend Capital, Tairui Investment, ZAI Laboratory.
DMed appears to refer to D.med Technologies (a medical‑device design & engineering firm that styles itself “D.med”) rather than Disney’s DMED (Disney Media & Entertainment Distribution); I’ll profile D.med Technologies below. If you meant a different “dMed” (for example Disney’s DMED or another firm), tell me and I’ll switch focus. [D.med Technologies company site][1][2]
High‑Level Overview
D.med Technologies is a multidisciplinary medical‑device design and development services company that helps device makers take concepts through regulatory clearance and market launch, combining software, electronics, clinical/regulatory and cybersecurity expertise in one group [1][2]. Their team of roughly 80+ specialists (across D.med Software, D.med Consulting, D.med Medical and GPE) reports experience across >500 projects and work on Class II/III devices, connected/IoT products and clinical studies[1][2].
Origin Story
D.med Technologies is presented as a unified organization merging several specialist teams (D.med Software, D.med Consulting, D.med Medical and GPE) into a single group of +80 experts to deliver integrated medical device development services; their web content emphasizes multidisciplinary consolidation rather than a single‑founder narrative[1][2]. The D.med Software division describes itself as a fast‑growing team of cybersecurity, embedded software and electronic developers working alongside project managers and clinical specialists, and cites strategic partnerships (for example D.Med Consulting GmbH) for clinical/extracorporeal expertise[3]. Early traction is framed as completing over 500 collaborative projects and multiple international market launches across class II/III products[1].
Core Differentiators
Role in the Broader Tech Landscape
D.med sits at the intersection of several industry trends: the shift to connected and software‑defined medical devices, rising regulatory scrutiny (especially around cybersecurity and software as a medical device), and the outsourcing of specialized R&D to accelerate time‑to‑market. Their timing matters because device makers increasingly need integrated teams that can deliver software, hardware and regulatory evidence together—something many startups and smaller OEMs lack internally[2][3]. Market forces in their favor include growing demand for remote monitoring/wearables, stricter cybersecurity and clinical evidence expectations, and cost pressure that drives outsourcing of complex engineering tasks. By enabling startups and SMEs to bring compliant products to market, D.med influences the ecosystem by lowering technical and regulatory barriers to commercialization[1][2].
Quick Take & Future Outlook
What’s next: expect growth focused on connected devices, stronger cybersecurity offerings, and further international regulatory services as demand for remote monitoring and AI‑enabled medical software rises[2][3]. Trends that will shape their journey include tighter regulatory guidance for software and AI in medical devices, growing payer interest in digital therapeutics and remote care, and consolidation among engineering service providers—each creating opportunities for a multidisciplinary partner like D.med. If they continue to scale their integrated teams and demonstrate successful market launches (and publish more case studies or regulatory successes), they can position themselves as a go‑to outsourced R&D partner for high‑risk, software‑intensive medical devices[1][2][3].
If you want, I can:
dMed has raised $214.0M across 5 funding rounds. Most recently, it raised $50.0M Series C in July 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 10, 2021 | $50.0M Series C | Springhill Fund | Fidelity Management & Research Company, Hongshan Capital Group (Sequoia Capital China), Kaiser Permanente, Rock Springs Capital, Superstring Capital |
| Dec 1, 2020 | $100.0M Series C | Fidelity Management & Research Company | Qiming Venture Partners, Hongshan Capital Group (Sequoia Capital China), Kaiser Permanente, Lilly Asia Ventures, Vivo Capital |
| Oct 1, 2019 | $50.0M Series B | Vivo Capital | Qiming Venture Partners, Legend Capital, Lilly Asia Ventures |
| Jun 1, 2018 | $6.0M Series B | Qiming Venture Partners | |
| Nov 1, 2016 | $8.0M Series A | Qiming Venture Partners | Tairui Investment, ZAI Laboratory |